1st human clinical trial of artificial pancreas yields positive result

   Jun 11, 11:22 am

Washington, June 11 (ANI): Results from the first feasibility study of an advanced first-generation artificial pancreas system have indicated that the Hypoglycemia-Hyperglycemia Minimizer (HHM) System was able to automatically predict a rise and fall in blood glucose and correspondingly increase and-or decrease insulin delivery safely.

The HHM System included a continuous, subcutaneous insulin pump, a continuous glucose monitor (CGM) and special software used to predict changes in blood glucose.

It was conducted by Animas Corporation in collaboration with JDRF as part of an ongoing partnership to advance the development of a closed-loop artificial pancreas system for patients with Type 1 diabetes.

"The successful completion of this study using the HHM System in a human clinical trial setting is a significant step forward in the development of an advanced first-generation artificial pancreas system," Dr. Henry Anhalt, Animas Chief Medical Officer and Medical Director of the Artificial Pancreas Program, said.

"It lays the foundation for subsequent clinical trials, bringing us one step closer to making the dream of an artificial pancreas a reality for millions of people living with Type 1 diabetes," he said.

In June 2011, Animas received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to proceed with human clinical feasibility studies for the development of a closed-loop artificial pancreas system.

The company partnered with the JDRF in January 2010 to begin developing such an automated system to help people living with Type 1 diabetes better control their disease.

"We are encouraged by the results of the first human trials in this partnership with Animas," Aaron Kowalski, Assistant Vice President of Research at JDRF, said.

"An artificial pancreas system that can not only detect, but can predict high and low blood sugar levels and make automatic adjustments to insulin delivery would be a major advance for people with Type 1 diabetes. Such a system could alleviate a huge burden of managing this disease," Kowalski said.

The trial was a non-randomized, uncontrolled feasibility study of 13 participants with Type 1 diabetes at one trial site in the United States. The investigational Hypoglycemia-Hyperglycemia Minimizer (HHM) system was studied for approximately 24 hours for each study participant during periods of open and closed loop control via a model predictive control algorithm with a safety module run from a laptop platform.

Insulin and food variables were manipulated throughout the study time period to challenge and assess the system.

The primary endpoint was to evaluate the ability of the algorithm to predict a rise and fall in glucose above or below set thresholds and to command the pump to increase, decrease, suspend and/or resume insulin infusion accordingly.

The secondary endpoint was to understand the HHM system's ability to safely keep glucose levels within a target range and to provide guidance for future system development. The study also examined the relationship between CGM trends and the control model's algorithm for insulin delivery.

The findings were presented today at the 72nd Annual American Diabetes Association Meeting in Philadelphia. (ANI)

Functional liver cells developed using stem cells Jul 31, 10:40 am
Washington DC, July 31 (ANI): A group of scientists have claimed to have created functional liver cells from human embryonic and genetic engineered stem cells.
Full Story
India demonstrates capability of launching Geosynchronous satellite Jul 30, 6:04 pm
New Delhi, July 30 (ANI): India has demonstrated the capability of launching 1.4 ton class of satellites using Polar Satellite Launch Vehicle (PSLV) and 2 ton class of satellites using Geosynchronous Satellite Launch Vehicle (GSLV) Mk II to Geosynchronous Transfer Orbit (GTO).
Full Story
Blocking this gene cuts excessive fat, finds study Jul 30, 12:55 pm
Washington DC, July 30 (ANI): Scientists have found that it is possible to reduce fat by blocking the expression of a certain gene in patients.
Full Story
ICAR lab artificially breeds milkfish for first time in India Jul 29, 4:28 pm
Chennai, July 29 (ANI): For the first time in India, Chennai-based Central Institute of Brackishwater Aquaculture (CIBA) succeeded in artificially breeding milkfish (Chanos chanos), locally known as "Paal Kendai" or "Poo Meen". Milkfish has the ability to grow in brackish water, seawater and even adapts to freshwater conditions.
Full Story
Comments

LATEST STORIES
TOP VIDEO STORIES
PHOTO GALLERY